Several ADCs have been approved for clinical use, including: - [Brentuximab Vedotin](): Targets CD30 and is used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. - [Trastuzumab Emtansine (T-DM1)](): Targets HER2 and is used in HER2-positive breast cancer. - [Inotuzumab Ozogamicin](): Targets CD22 and is used in relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
